{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+or+Recurrent+Squamous+Cell+Carcinoma+of+the+Lung",
    "query": {
      "condition": "Metastatic or Recurrent Squamous Cell Carcinoma of the Lung"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 40,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+or+Recurrent+Squamous+Cell+Carcinoma+of+the+Lung&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T17:29:03.022Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01528137",
      "title": "Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Salivary Gland Squamous Cell Carcinoma",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Oral Cavity",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVA Squamous Cell Carcinoma of the Larynx",
        "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Verrucous Carcinoma of the Larynx",
        "Stage IVA Verrucous Carcinoma of the Oral Cavity",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVB Squamous Cell Carcinoma of the Larynx",
        "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Verrucous Carcinoma of the Larynx",
        "Stage IVB Verrucous Carcinoma of the Oral Cavity",
        "Stage IVC Salivary Gland Cancer",
        "Stage IVC Squamous Cell Carcinoma of the Larynx",
        "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVC Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Verrucous Carcinoma of the Larynx",
        "Stage IVC Verrucous Carcinoma of the Oral Cavity",
        "Tongue Cancer"
      ],
      "interventions": [
        {
          "name": "talactoferrin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2012-05",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-02",
      "last_synced_at": "2026-06-25T17:29:03.022Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01528137"
    },
    {
      "nct_id": "NCT05736731",
      "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Solid Tumor",
        "Pancreatic Cancer",
        "Pancreatic Neoplasms",
        "Pancreas Cancer",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Recurrent",
        "Non-Small Cell Squamous Lung Cancer",
        "NSCLC",
        "NSCLC, Recurrent",
        "Colorectal Cancer",
        "Colorectal Neoplasms",
        "Colorectal Adenocarcinoma",
        "CRC",
        "Colorectal Cancer Metastatic",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "A2B530",
          "type": "BIOLOGICAL"
        },
        {
          "name": "xT-Onco with HLA-LOH Assay",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2023-04-28",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-06-25T17:29:03.022Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05736731"
    },
    {
      "nct_id": "NCT00998192",
      "title": "A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic or Recurrent Squamous Cell Carcinoma of the Lung"
      ],
      "interventions": [
        {
          "name": "REOLYSIN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Oncolytics Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2009-10",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2016-03-31",
      "last_synced_at": "2026-06-25T17:29:03.022Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Ocala, Florida • Niles, Illinois + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Niles",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Armonk",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00998192"
    },
    {
      "nct_id": "NCT06238479",
      "title": "A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumor",
        "Recurrent Solid Tumor",
        "Advanced Solid Tumor",
        "Urinary Bladder Neoplasm",
        "Triple Negative Breast Cancer",
        "Non-small Cell Lung Cancer",
        "Esophageal Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Prostate Cancer",
        "Renal Pelvis Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "LY4101174",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 490,
      "start_date": "2024-03-05",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-25T17:29:03.022Z",
      "location_count": 9,
      "location_summary": "Orlando, Florida • Atlanta, Georgia • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06238479"
    },
    {
      "nct_id": "NCT05597839",
      "title": "Study of DF9001 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "DF9001",
          "type": "DRUG"
        },
        {
          "name": "KEYTRUDA® (pembrolizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dragonfly Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-11-15",
      "completion_date": "2025-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-06-25T17:29:03.022Z",
      "location_count": 17,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05597839"
    },
    {
      "nct_id": "NCT00031681",
      "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Adult Primary Liver Cancer",
        "Carcinoma of the Appendix",
        "Estrogen Receptor-negative Breast Cancer",
        "Extensive Stage Small Cell Lung Cancer",
        "Gastrointestinal Stromal Tumor",
        "HER2-negative Breast Cancer",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Ovarian Sarcoma",
        "Ovarian Stromal Cancer",
        "Progesterone Receptor-negative Breast Cancer",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Anal Cancer",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor",
        "Recurrent Breast Cancer",
        "Recurrent Cervical Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Esophageal Cancer",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Recurrent Gastric Cancer",
        "Recurrent Gastrointestinal Carcinoid Tumor",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Recurrent Pancreatic Cancer",
        "Recurrent Prostate Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Small Cell Lung Cancer",
        "Recurrent Small Intestine Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Small Intestine Adenocarcinoma",
        "Small Intestine Leiomyosarcoma",
        "Small Intestine Lymphoma",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Anal Cancer",
        "Stage IV Basal Cell Carcinoma of the Lip",
        "Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Endometrial Carcinoma",
        "Stage IV Esophageal Cancer",
        "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Gastric Cancer",
        "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Lymphoepithelioma of the Oropharynx",
        "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Ovarian Germ Cell Tumor",
        "Stage IV Pancreatic Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity",
        "Stage IVA Cervical Cancer",
        "Stage IVB Cervical Cancer",
        "Triple-negative Breast Cancer",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "7-hydroxystaurosporine",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "diagnostic laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2001-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-30",
      "last_synced_at": "2026-06-25T17:29:03.022Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00031681"
    },
    {
      "nct_id": "NCT02955290",
      "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Head and Neck Squamous Cell Carcinoma",
        "Lung Non-Small Cell Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "PD-L1 Positive",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Unresectable Lung Non-Small Cell Carcinoma",
        "Advanced Squamous Non-Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2016-12-22",
      "completion_date": "2027-12-09",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-06-25T17:29:03.022Z",
      "location_count": 5,
      "location_summary": "Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Roslyn",
          "state": "New York"
        },
        {
          "city": "West Islip",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02955290"
    },
    {
      "nct_id": "NCT00004065",
      "title": "Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Leukemia",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "tanespimycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-07",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-06-25T17:29:03.022Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004065"
    },
    {
      "nct_id": "NCT02495896",
      "title": "Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic Pancreatic Adenocarcinoma",
        "Non-Resectable Cholangiocarcinoma",
        "Pancreatic Adenocarcinoma",
        "Recurrent Gallbladder Carcinoma",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Stage III Pancreatic Cancer",
        "Stage IIIA Gallbladder Cancer",
        "Stage IIIA Non-Small Cell Lung Cancer",
        "Stage IIIB Gallbladder Cancer",
        "Stage IIIB Non-Small Cell Lung Cancer",
        "Stage IV Gallbladder Cancer",
        "Stage IV Non-Small Cell Lung Cancer",
        "Stage IV Pancreatic Cancer",
        "Unresectable Gallbladder Carcinoma",
        "Unresectable Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Recombinant EphB4-HSA Fusion Protein",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2015-09-03",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-06-25T17:29:03.022Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Newport Beach, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02495896"
    },
    {
      "nct_id": "NCT04777994",
      "title": "Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-CLS-484",
          "type": "DRUG"
        },
        {
          "name": "Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)",
          "type": "DRUG"
        },
        {
          "name": "Programmed Cell Death-1 (PD-1) Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calico Life Sciences LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 248,
      "start_date": "2021-03-09",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-06-25T17:29:03.022Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • New Haven, Connecticut • Baltimore, Maryland + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04777994"
    }
  ]
}